JP2010096506A5 - - Google Patents

Download PDF

Info

Publication number
JP2010096506A5
JP2010096506A5 JP2008264794A JP2008264794A JP2010096506A5 JP 2010096506 A5 JP2010096506 A5 JP 2010096506A5 JP 2008264794 A JP2008264794 A JP 2008264794A JP 2008264794 A JP2008264794 A JP 2008264794A JP 2010096506 A5 JP2010096506 A5 JP 2010096506A5
Authority
JP
Japan
Prior art keywords
cancer
heavy chain
tissue
clathrin heavy
discrimination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008264794A
Other languages
Japanese (ja)
Other versions
JP2010096506A (en
JP5133842B2 (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2008264794A priority Critical patent/JP5133842B2/en
Priority claimed from JP2008264794A external-priority patent/JP5133842B2/en
Publication of JP2010096506A publication Critical patent/JP2010096506A/en
Publication of JP2010096506A5 publication Critical patent/JP2010096506A5/ja
Application granted granted Critical
Publication of JP5133842B2 publication Critical patent/JP5133842B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (10)

癌が疑われる患者または癌患者由来の組織検体中における、クラスリンヘビーチェインおよび／またはホルムイミノトランスフェラーゼシクロデアミナーゼの発現レベルを測定して、癌部と非癌部とを判別することを特徴とする、癌が疑われる患者または癌患者由来の組織の癌部と非癌部の判別方法。   It is characterized by measuring the expression level of clathrin heavy chain and / or formiminotransferase cyclodeaminase in a patient suspected of cancer or a tissue sample derived from a cancer patient to distinguish between a cancerous part and a non-cancerous part A method for discriminating cancerous and non-cancerous parts of a patient suspected of having cancer or tissue derived from a cancer patient. 癌が原発性肝細胞癌である、請求項１に記載の判別方法。   The method according to claim 1, wherein the cancer is primary hepatocellular carcinoma. 組織検体中のクラスリンヘビーチェインおよびホルムイミノトランスフェラーゼシクロデアミナーゼの発現レベルを測定する、請求項１または２に記載の判別方法。   The discrimination method according to claim 1 or 2, wherein the expression level of clathrin heavy chain and formiminotransferase cyclodeaminase in a tissue sample is measured. 抗クラスリンヘビーチェイン抗体および／または抗ホルムイミノトランスフェラーゼシクロデアミナーゼ抗体を用いて、組織免疫染色法により組織検体中のクラスリンヘビーチェインおよび／またはホルムイミノトランスフェラーゼシクロデアミナーゼを測定する、請求項１から３のいずれか１項に記載の判別方法。   The clathrin heavy chain and / or formiminotransferase cyclodeaminase in a tissue specimen is measured by a tissue immunostaining method using an anti-clathrin heavy chain antibody and / or an anti-formiminotransferase cyclodeaminase antibody. The discrimination method according to any one of the above. 癌が疑われる患者または癌患者の結節由来の組織検体中における、クラスリンヘビーチェインおよび／またはホルムイミノトランスフェラーゼシクロデアミナーゼの発現レベルを測定して、悪性結節と良性結節を判別する、請求項１から４のいずれか１項に記載の判別方法。   The malignant nodule and the benign nodule are discriminated by measuring the expression level of clathrin heavy chain and / or formiminotransferase cyclodeaminase in a tissue sample derived from a patient suspected of cancer or a nodule of the cancer patient. 5. The determination method according to any one of 4 above. 組織検体中のクラスリンヘビーチェインおよびホルムイミノトランスフェラーゼシクロデアミナーゼの少なくとも一つの発現レベルを測定して、癌の分化度を判別する、請求項１から５のいずれか１項に記載の判別方法。   The discrimination method according to any one of claims 1 to 5, wherein the differentiation level of cancer is discriminated by measuring at least one expression level of clathrin heavy chain and formiminotransferase cyclodeaminase in a tissue sample. 組織検体中のクラスリンヘビーチェインの発現レベルを、抗クラスリンヘビーチェイン抗体を用いて、組織免疫染色法により測定することを特徴とする、肝癌、膀胱癌、乳癌、肺癌、卵巣癌、前立腺癌、皮膚癌および甲状腺癌から選ばれる癌の組織判別法。 The expression level of clathrin heavy chain in tissue specimens is measured by tissue immunostaining using anti-clathrin heavy chain antibody, liver cancer, bladder cancer, breast cancer, lung cancer, ovarian cancer, prostate cancer A tissue discrimination method for cancer selected from skin cancer and thyroid cancer . 抗クラスリンヘビーチェイン抗体および／または抗ホルムイミノトランスフェラーゼシクロデアミナーゼ抗体を含む、癌が疑われる患者または癌患者由来の組織の癌部と非癌部とを判別するための判別試薬。 A discrimination reagent for discriminating between cancerous and non-cancerous parts of a patient suspected of cancer or a tissue derived from a cancer patient, comprising an anti-clathrin heavy chain antibody and / or an anti-formiminotransferase cyclodeaminase antibody. 抗クラスリンヘビーチェイン抗体および／または抗ホルムイミノトランスフェラーゼシクロデアミナーゼ抗体を含む、請求項８に記載の判別試薬。 The discrimination reagent according to claim 8 , comprising an anti-clathrin heavy chain antibody and / or an anti-formiminotransferase cyclodeaminase antibody. 組織免疫染色法により判別するための、請求項８または９に記載の判別試薬。 The discrimination reagent according to claim 8 or 9 for discrimination by tissue immunostaining.
JP2008264794A 2008-10-14 2008-10-14 Method for discriminating between cancerous part and non-cancerous part of patient suspected of cancer or tissue derived from cancer patient, and discrimination reagent used therefor Expired - Fee Related JP5133842B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008264794A JP5133842B2 (en) 2008-10-14 2008-10-14 Method for discriminating between cancerous part and non-cancerous part of patient suspected of cancer or tissue derived from cancer patient, and discrimination reagent used therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008264794A JP5133842B2 (en) 2008-10-14 2008-10-14 Method for discriminating between cancerous part and non-cancerous part of patient suspected of cancer or tissue derived from cancer patient, and discrimination reagent used therefor

Publications (3)

Publication Number Publication Date
JP2010096506A JP2010096506A (en) 2010-04-30
JP2010096506A5 true JP2010096506A5 (en) 2011-12-01
JP5133842B2 JP5133842B2 (en) 2013-01-30

Family

ID=42258307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008264794A Expired - Fee Related JP5133842B2 (en) 2008-10-14 2008-10-14 Method for discriminating between cancerous part and non-cancerous part of patient suspected of cancer or tissue derived from cancer patient, and discrimination reagent used therefor

Country Status (1)

Country Link
JP (1) JP5133842B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5257788B2 (en) * 2009-12-02 2013-08-07 日東紡績株式会社 Immunoassay method for complex of clathrin heavy chain and its autoantibody, kit used therefor, and cancer determination method using the same
TWI485158B (en) * 2011-10-04 2015-05-21 Academia Sinica A novel anti-clathrin heavy chain monoclonal antibody for inhibition of tumor angiogenesis and growth and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109809A1 (en) * 2006-03-23 2007-09-27 Invitrogen Corporation Methods and reagents for in vivo imaging of cancer cell lines
BRPI0712629C1 (en) * 2006-06-20 2021-07-27 Genentech Inc method for detecting apoptosis and method for identifying a human cancer cell
US7759542B2 (en) * 2007-08-01 2010-07-20 National Yang-Ming University Glycine N-methyltransferase (GNMT) animal model and use thereof

Similar Documents

Publication Publication Date Title
Jin et al. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma
Wang et al. Advances in the early diagnosis of hepatocellular carcinoma
Cai et al. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies
Knudsen et al. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy
Di Tommaso et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma
Garg et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes
Abd el-Latif et al. The sensitivity of initial transurethral resection or biopsy of bladder tumor (s) for detecting bladder cancer variants on radical cystectomy
Torbenson Hepatic adenomas: classification, controversies, and consensus
Kunju et al. Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations
Cillo et al. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation
Wang et al. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation
JP2009522578A5 (en)
BRPI0311233B8 (en) in vitro methods for screening a patient for hepatocellular carcinoma (hcc), and for diagnosing hcc in a patient, as well as a method and kit for detecting or determining the level of gpc3 in a specimen
Devriese et al. Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials
Bailey et al. Performance of 68 Ga-PSMA PET/CT for prostate cancer management at initial staging and time of biochemical recurrence
Alkotyfan et al. Cyfra 21-1 as a Tumor Marker for Follow-up of Patients with Squamous Cell Carcinoma of the Oropharnyx
RU2012129913A (en) DIAGNOSIS METHOD FOR A MALIGNANT TUMOR
Lu et al. α-Fetoprotein mRNA in situ hybridisation is a highly specific marker of hepatocellular carcinoma: a multi-centre study
Luo et al. Prognostic relevance of Id-1 expression in patients with resectable esophageal squamous cell carcinoma
Witjes et al. Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers
Provenzano et al. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple‐negative tumours
JP2010096506A5 (en)
Salomao et al. Recent advances in the classification of hepatocellular carcinoma
Truta et al. Novel non invasive diagnostic strategies in bladder cancer
CN106636375A (en) Marker miR-126-3P for HER-2 positive breast cancer tissue, and application and diagnosis kit of marker miR-126-3P